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Prediction of breast cancer response to Neoadjuvant Chemotherapy (NACT) is an urgent
need to promptly direct non-responder patients to alternative therapies. Infiltrating T
lymphocytes, namely cytotoxic T lymphocytes (CTLs) have been appointed as predictors
of response. However, cancer cells have the ability to dampen CTLs’ activity and
thus, the prognostic value of the CTLs, per se, is debatable. Here, we disclose that
more than the occurrence of CTLs, it is their activation state, revealed by HLA-DR
expression, that can accurately predict response to NACT. Flow cytometry analysis of
breast cancer biopsies showed that the frequency of CTLs and other lymphocytes were
similar regardless disease stage and between NACT responders and non-responders.
However, only breast cancer patients without axillary lymph node metastasis and
NACT responders have HLA-DRhi CTLs. Interestingly, HLA-DR levels in tumor CTLs
is correlated with HLA-DR levels in systemic CTLs. These HLA-DR+ CTLs produce
IFN-γ and Granzyme B, enlightening their effector and probable anti-tumor activity profile.
Moreover, the level of HLA-DR in CTLs is negatively correlated with the level of HLA-DR in
T regulatory lymphocytes and with immunosuppressive and pro-tumor molecules in the
tumor microenvironment. Hence, HLA-DR levels in CTLs is a highly sensitive and specific
potential predictive factor of NACT-response, which can be assessed in blood to guide
therapeutic decisions.
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INTRODUCTION
Breast cancer remains one of the main causes of cancer-related deaths in women worldwide
(1). The disease can be divided in three different subtypes—hormone-positive (estrogen and/or
progesterone—ER+ and/or PR+), human epidermal growth factor receptor 2 (HER2) positive and
triple negative breast cancer (TNBC), which lacks the three mentioned markers. In the past years,
advances in breast cancer treatment have been made, namely with the introduction of preoperative
neoadjuvant chemotherapy (NACT) in selected cases of advanced tumors (with tumor size larger
than 2 cm and/or disease extension to axillary lymph node) or inflammatory breast cancer. This
treatment is effective in reducing the size of the primary tumor, allowing breast conservation in
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selected cases, and some patients achieve a pathological complete
response (pCR) (2). However, this only happens in less than
50% of the patients (3, 4) and residual disease after NACT is a
strong predictor of relapse (2, 5). Hence, it is essential to find a
good marker of response to NACT, in order to promptly direct
patients to alternative therapies, therefore avoiding the misuse of
resources and the potential toxicity associated with NACT.
Increasing evidence suggests that anti-cancer chemotherapy
is influenced by the immune system (6). Indeed, tumors can
be heavily infiltrated by immune cells, in particular, tumor
infiltrating lymphocytes (TILs), which have been associated
with good prognosis in various cancers, including breast
cancer (6). Several reports have been advocating that TILs,
especially cytotoxic T lymphocytes (CTLs), due to their anti-
tumor cytotoxic activity, could serve as a robust marker
for predicting pCR rate after NACT (7). However, even
with an effort to standardize TILs evaluation (8), data
are still conflicting, and other reports describe that TILs
and their subsets could not show any predictive value,
particularly in hormone-positive subtype (6), possibly because
these patients are further treated with endocrine therapy for
years. Furthermore, T regulatory cells (Tregs), by suppressing
the effector immune response, are normally associated with poor
prognosis. However, they are still described to have an ambiguous
role (9).
Actually, tumor cells have mechanisms to escape the immune
system, and the activity of CTLs can be hampered by them.
For instance, tumors may express inhibitory molecules like
programmed death-ligand 1 (PD-L1) which bind the inhibitory
receptor programmed death 1 (PD-1) in CTLs, inducing negative
regulatory pathways that limit the activity of these cells (10,
11). Other inhibitory immune checkpoints, such as cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) and the secretion
of immunosuppressing molecules, such as IL-10, TGF-β or
Indoleamine 2, 3-Dioxygenase (IDO), could also directly or
indirectly (by recruiting and activating Tregs), negatively impact
CTLs’ activity (10, 11).
Considering the aforementioned, the presence of CTLs per
se provides limited information regarding NACT outcome, and
the activation level of these cells, as a result of the overall tumor
immune status, should be taken into account in order to better
predict response to NACT.
HLA-DR is recognized as a marker of T cell activation (12, 13)
and has been shown to be increased in CTLs in autoimmune
diseases (14) and in patients with HIV infection (15).
In this work, by flow cytometry analysis of fresh samples,
we demonstrated that a subset of CTLs expressing HLA-
DR is enriched in breast cancer without axillary lymph node
metastasis comparing with breast cancer with axillary lymph
node metastasis, although the average frequency of CTLs is
similar between groups. Furthermore, biopsies from NACT
responders also have HLA-DRhi CTLs, while no differences
were observed concerning the density of CTLs between NACT
responders and non-responders. Interestingly, the profile of
HLA-DRhi CTLs was negatively correlated with high levels of
pro-tumor and immunosuppressive molecules in the tumor
immune microenvironment.
TABLE 1 | Characteristics of patients enrolled in this study (age, body mass
index, and menopause).
Age Median−58 (range: 35–87)
Body mass index (BMI) Median−26.03 (range: 17.04–39.74)
Post-menopause 62.30%
ER+ (PR –/+) 68%
HER2+ including triple positive
breast cancer
16%
TNBC 16%
Grade G1–8.26%
G2–58.68%
G3–33.06%
Ki67 Median−21.75% (range: 2–98.4%)
Dimension (mm) Median−25 (range: 7–90)
Axillary lymph node invasion status Negative−51.09%
Positive−48.91%
Response (if NACT) Good response−43.33%
Bad response−56.67%
Clinical data, such as subtype of breast cancer, grade, Ki67, tumor dimension, node status
and response to treatment are also described.
Therefore, we propose that HLA-DR+ CTLs have the
potential to be used in clinical settings to predict breast cancer
patients’ response to NACT, with the advantage of being easily
accessed in blood.
MATERIALS AND METHODS
Patient Samples
Forty-eight fresh biopsies and ninety-six non-matched
surgical samples of breast cancer (BC) patients were collected in
saline solution. Matched peripheral blood from 31 BC patients
was collected in Vaccutainer tubes with EDTA (BD Biosciences).
Whole blood from 13 healthy donors was also collected for
comparison studies. For in vitro studies, patients’ peripheral
blood mononuclear cells (PBMCs) were isolated by a Ficoll
gradient (Merck Milipore) and PBMCs from buffy coats of 5
healthy donors, donated by Instituto Português do Sangue e da
Transplantação, were used for control purposes. Formalin-fixed
paraffin embedded (FFPE) tissue was collected from 12 matched
patients divided according to the axillary lymph node invasion
status and response to neoadjuvant chemotherapy (NACT). A
summary of the patients characteristics are given in Table 1.
Fresh samples were handled within 1-day post collection.
Fresh tumors and biopsies were mechanically dissociated with a
BDMedicon (BD Bioscience), filtered and washed once with PBS
1X. PBMCs after isolation were cryopreserved in 90% fetal bovine
serum (FBS, Biowest) and 10% dimethyl sulfoxide (DMSO, Sigma
Aldrich) until further use.
Samples were gathered from Hospital CUF Descobertas,
Hospital Prof. Doutor Fernando Fonseca and Hospital de Vila
Franca de Xira. For each patient, written informed consent and
approval by the Ethical Committee of the hospitals and of the
NOVAMedical School were obtained. The study is in compliance
with the Declaration of Helsinki.
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Antibodies
For flow cytometry analysis, tumor and blood samples were
stained with a cocktail of monoclonal mouse anti-human
conjugated antibodies (mAbs): anti-CD45-PercP (clone HI30),
anti-CD3-PercP (HIT3a), anti-CD3-APC (UCHT1), anti-CD19-
PE (HIB19), anti-CD15-PE (HI98), anti-CD161-FITC (HP-
3G10), anti-CD4-FITC (OKT4), anti-CD8-PE (HIT8a), anti-
HLA-DR-APC (L243), anti-CD127-PE-Cy7 (A019D5), anti-
CD1c-APC-Cy7 (L161), anti-CD163-PE (GHI/61), anti-CD206-
APC-Cy7 (15–2), anti-PD-1-FITC (EH12.2H7), anti-PD-L1-
APC (29E2A3), anti-CTLA4-PE (L3D10), anti-CD69-APC-
Cy7 (FN50), anti-Tim3-APC (F38-2E2), anti-IL-8-APC (E8N1),
anti-IFN-γ-PE (4S.B3), anti-IFN-γ-APC-Cy7 (4S.B3), anti-
Granzyme B-FITC (QA16A02), anti-IL-1β-FITC (JK1B-1), anti-
IL-2-PE-Cy7 (MQ1-17H12), anti-IL-6-APC (MQ2-13A5), anti-
IL-17-FITC (BL168), anti-IL-23/IL-12-PE (C11.5), anti-TGF-β-
APC (TW4-6H10), all from Biolegend; anti-IDO-PE (eyedio)
and anti-IL-10-FITC (BT-10), both from eBioscience; anti-
CD25-PE (MEM-181) and anti-CD11b-FITC (LT11) from
ImmunoTools.
The antibodies used for immunofluorescence were: mouse
monoclonal anti-human CD8 (32-M4) from Santa Cruz
Biotechnology and rabbit polyclonal anti-human HLA-DRA
from Sigma Aldrich.
Flow Cytometry
BC samples were stained with BD HorizonTM Fixable Viability
Stain 450 (BD Biosciences) and with the cocktail of antibodies,
fixed and permeabilized with Fix/Perm kit (eBiosciences)
followed by intracellular staining. For whole blood, staining with
antibodies was followed by a step of red blood cells lysis with RBC
lysis buffer (Biolegend).
For immunophenotyping we classified cytotoxic T
lymphocytes as CD45+/CD3+/CD8+; helper T lymphocytes as
CD45+/CD3+/CD4+; regulatory T lymphocytes as CD45+/
CD3+/CD4+/CD25hi/CD127lo; B lymphocytes as CD45+/
CD19+; NK cells as CD45+/CD161+; M2 macrophages as
CD45+/CD11b+/CD163+/CD206+; M1 macrophages as
CD45+/CD11b+/CD163negative/CD206negative; dendritic
cells as CD45+/CD1c+; and neutrophils as CD45+/CD15+.
Data was acquired in BD FACS Canto II cell analyzer
with FACSDiva Software v8.0.1 (BD Biosciences) and the
results were analyzed using FlowJo software v10. The data
is presented as percentage of the populations in respect
to the gate of single cells, following the gate strategy
represented in Figure S1. To analyze the expression levels
of HLA-DR in CTLs or Tregs, we considered the median
fluorescent intensity of positive population and normalized
it to the negative population, as previously described (16).
The negative population was superimposed with the unstained
control.
Ex vivo Stimulation Assay
Isolated PBMCs were cultured in 96 well-plates with U bottom
(Sigma Aldrich) with RMPI-1640 (Gibco) supplemented with
10% FBS and 1% Penicillin/Streptomycin (GE Healthcare).
Stimulation was performed during 4 h (or overnight for HLA-
DR expression) with 35 ng/mL of phorbol 12-myristate 13-
acetate (PMA, Sigma Aldrich) and 1µg/mL of ionomycin (Merck
Milipore). Brefeldin A (Biolegend) was added for 4 h to stop
the extracellular transport. Cells were collected and stained with
mAbs and analyzed by flow cytometry.
Immunofluorescence
Immunofluorescence was performed in formalin-fixed paraffin
embedded tissues (FFPE). Paraffin was removed in xylene
(10min) and passed through a gradient of alcohol (100, 96,
and 70%) and dH2O. Antigen retrieval was performed in 2
cycles of 15 mins each with 1mM EDTA (Sigma Aldrich) with
0.05% Tween-20 (Sigma Aldrich) in the microwave (900W).
The slides were permeabilized with PBS 1X + 0.3% Triton
X-100 (ACROS Organics) and blocked with PBS 1X + 0.1%
Triton X-100+ 1% bovine serum albumin (BSA, Sigma Aldrich)
+ 1.5% goat serum (Sigma Aldrich). Staining with primary
antibody (1:100) was performed overnight at 4◦C followed by
the incubation with secondary antibody for 2 h in the dark at
room temperature. Counterstaining was performed with 4′,6-
diamidino-2-phenylindole (DAPI; 0.001 mg/mL in PBS, Sigma-
Aldrich) and the slides were mounted in Fluorescent Mounting
Media (DAKO). Images were taken in a confocal microscope
(LSM710, Zeiss) and analyzed in Fiji software (17).
ELISA
The patients’ plasma was isolated from whole blood and frozen
for further cytokine analysis. The quantity of secreted cytokines
was measured using ELISA technique, namely human IL-10
(ImmunoTools) and IFN-γ (Biolegend) kits were used according
to the manufacturer’s instructions. Cytokine concentration was
calculated using the specific standard curves.
Cell Sorting
PBMCs were stained with the viability dye followed by the
mAbs anti-CD3-PercP, anti-CD8-PE and anti-HLA-DR-
APC. Cells were sorted in CD3+/CD8+/HLA-DR+ and
CD3+/CD8+/HLA-DRnegative in a FACS Aria III (BD
Biosciences) with an efficiency of 98% (Figure S2).
qRT-PCR
Total RNA of sorted cells was extracted using RNeasy Micro Kit
(Qiagen) and reverse transcribed with Transcriptor High Fidelity
cDNA synthesis kit (Roche). Quantitative real-time PCR (qRT-
PCR) was performed with several primers, described in Table 2,
using Roche LightCycler 480 and FastStart Essential DNA Green
Master Mix (Roche). Cyclic conditions were: 95◦C for 10min,
followed by 45 amplification cycles, each consisting of 10 s at
95◦C, 10 s at 56◦C, and 20 s at 72◦C, and finally a melting step
of 10 s at 95◦C, 60 s at 65◦C, and 1 s at 97◦C.
The relative mRNA levels were normalized against the values
obtained for the housekeeping gene RPL13A and calculated by
the formula 2−1Ct × 1000 that gives us the number of mRNA
molecules of the gene of interest per 1000 molecules of the
endogenous control (17, 18).
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TABLE 2 | Genes assessed with qRT-PCR and the primers used.
Gene Forward primer Reverse primer
TNFα AGATGATCTGACTGCCTGGG CTGCTGCACTTTGGAGTGAT
Granzyme B GGGGGACCCAGAGATTAAAA CCATTGTTTGGTCCATAGGAG
Perforin GCAATGTGCATGTGTCTGTG GGGAGTGTGTACCACATGGA
Eomes CAGCACCACCTCTACGAACA CGCCACCAAACTGAGATGAT
RPL13A TGCGTCTGAAGCCTACAAGA TCCGTAGCCTCATGAGCTGTT
In vitro Co-culture Assay
HS 578T cell line was maintained for 4 days in DMEM
(Biowest) with 10% FBS and 1% Penicillin/Streptomycin. After
that period, the supernatant and cells were harvested for the
co-culture. The supernatant was further centrifuged at 2000
rpm for 5min to eliminate cellular debris and possible cellular
antigens. PBMCs were plated on a 96 well plate U bottom in 4
conditions: monoculture, with the addition of the supernatant
from HS 578T culture, with a canonical stimulus of PMA and
ionomycin, and in co-culture on a ratio of 20:1 (PBMCs:HS
578T). PBMCs were collected 48 h after and analyzed by flow
cytometry.
Statistical Analysis
Statistical analysis was performed in GraphPad Prism v6 and
statistical significance was considered for p < 0.05. Comparison
between samples was performed by a nonparametric Mann-
Whitney test and correlations were calculated with Spearman
r-test. ROC curves were performed to assign a threshold to
divide NACT responders from non-responders. This analysis
was executed for both HLA-DR expressing CTLs and Tregs.
The determined area under the curve, sensitivity and specificity
were taken into account. The cut-off point for the HLA-DR
expression level in CTLs was a parameter also determined
by ROC curve analysis, considering the expression value that
corresponded to the maximum of sensitivity and specificity.
Paired t-test was used for the analysis of the co-culture
assay.
RESULTS
Clinical and Pathological Characteristics
For this study, 144 fresh samples (137 pre-treatment - 48
biopsies and 89 surgical specimens - and 7 post-NACT surgical
specimens) were collected prospectively. Data from these patients
are displayed in Table 1. Most patients have estrogen receptor
(ER) positive breast cancer, have high body mass index and are
post-menopausal.
These samples, except the post-NACT specimens, were used
in the first phase of the study for a global analysis of tumor
infiltrating immune populations. Then, aiming to find an
adequate biomarker of response to NACT, from these samples,
we used the first consecutive biopsies (n = 30) of patients that
were selected for NACT and related the activation status of their
lymphocytes with their response to treatment.
HLA-DR-expressing T Lymphocyte
Populations Can Distinguish Breast Cancer
Axillary Lymph Node Invasion Status
In the first phase of the study, and to get insight into the
composition and the role of immune infiltrate in breast cancer
(BC), we used a flow cytometry multipanel and analyzed several
immune populations (gate strategy in Figure S1) in 137 BC
patients prior to treatment implementation (48 biopsies and 89
surgical specimens). First, these patients were divided according
to the axillary lymph node invasion status. Patients without
axillary lymph node metastasis had a similar immunophenotype
when compared with patients with axillary lymph node
metastasis (Figures 1A–C). Indeed, although there was high
heterogeneity in the degree of immune infiltration between
patients, the average value of the frequency of T lymphocytes, B
lymphocytes, NK cells (Figure 1A), neutrophils, dendritic cells,
M1 andM2macrophages (Figure 1B) infiltrating the tumor, were
similar between the two groups of patients. Additionally, the
average value of the frequency of T lymphocyte populations—
helper (Th), cytotoxic (CTLs), and regulatory (Tregs)—were
similar between these two groups (Figure 1C).
Then, we considered the activation state of T lymphocyte
populations, by the analysis of established T cell activation
markers, CD69 and HLA-DR. Interestingly, this analysis
revealed significant differences between patients without axillary
lymph node invasion and patients with axillary lymph node
invasion, regarding the expression of HLA-DR. Namely, HLA-
DR expression level was higher in CTLs (p = 0.008) and lower
in Tregs (p = 0.001) in patients without axillary lymph node
metastasis when compared to patients with axillary lymph node
metastasis (Figures 1D,F). Furthermore, the expression of HLA-
DR in CTLs was negatively correlated with the expression of this
marker in Tregs (r =−0.54, p< 0.0001, Figures 1E, 6).
No differences were observed between patients of the two
groups regarding HLA-DR expression in Th cells, but we did
not discriminate between Th subsets (e.g., Th1, Th2, Th17), that
might influence cancer differently.
The analysis of CD69 expression in T lymphocyte populations
did not lead to the same result obtained by the analysis of HLA-
DR (data not shown). This may be due to the fact that CD69 is
an early, transiently expressed, activation marker of T cells (18),
while HLA-DR is increased later in the activation process of T
cells (19), remaining in the cell surface.
Besides dividing the patients regarding the presence or
absence of axillary lymph node invasion, we have also divided
them regarding breast cancer subtype (ER+, HER2+, or TNBC),
grade (G1, G2, or G3), age (<50 years old or >50 years old),
tumor dimension (<20 or >20mm) and body mass index (low,
normal or overweight). HLA-DR expression in T cell populations
was not significantly different in these other comparisons (results
not shown).
Thus, independently of BC subtype, expression of HLA-DR
in distinct T cell populations can differentiate patients with
axillary lymph node metastasis (HLA-DRhi Tregs) from patients
without axillary lymph node metastasis (HLA-DRhi CTLs).
These results suggested that more than simply the presence
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FIGURE 1 | HLA-DR expression in CTLs and Tregs can distinguish between patients without axillary lymph node metastasis (N–) and patients with axillary lymph node
metastasis (N+) contrarily to the percentage of distinct cell populations. (A) Percentage of leukocytes, T cells, B cells and NK cells in the tumor bulk from patients
without axillary lymph node metastasis (N–, gray triangles, n = 70, mean) and patients with axillary lymph node metastasis (N+, black dots, n = 67, mean).
(B) Percentage of dendritic cells (DCs), Neutrophils, M1 and M2 macrophages in the same populations. (C) Percentage of distinct T cell populations (helper T cells -
Th, cytotoxic T cells - CTLs and regulatory T cells - Tregs) in the tumor from both groups of patients. The percentage of each population was obtained in respect to
the gate in single cells (Figure S1). (D) Level of HLA-DR in Th, CTLs and Tregs in the tumor from patients with and without axillary lymph node invasion, expressed as
the median fluorescent intensity of positive population normalized relatively to negative population (**p < 0.01). (E) Correlation between HLA-DR+ CTLs and
HLA-DR+ Tregs in breast cancer samples (Spearman r = −0.54, p < 0.0001). (F) Representation of a flow cytometry analysis of HLA-DR expression gated on CTLs
and Tregs and differences between a tumor from a patient without axillary lymph node metastasis and a tumor from a patient with axillary lymph node metastasis.
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and/or the quantity of immune cells within the tumor immune
microenvironment, the quality (i.e., the activation state) of
certain immune cells, namely CTLs and Tregs, might be relevant
for cancer progression.
HLA-DRhi CTLs Are Associated With
Response to Neoadjuvant Chemotherapy
Considering that the HLA-DR expression in T lymphocyte
populations allows the distinction of axillary lymph node
invasion status, we asked if this trait could also be useful to
predict patients’ response to NACT. NACT was identical in
all patients and was composed of 4 cycles of anthracyclines
(doxorubicin) and cyclophosphamide, followed by 12 weeks of
paclitaxel. Only the addition of trastuzumab during paclitaxel
administration differed in HER2 patients. Biopsies from 30
patients that underwent NACT were here analyzed (pre-
treatment) by flow cytometry and, after the treatment, patients
were divided in responders and non-responders, according to
their radiological and pathological outcome. NACT responders
were classified as patients that achieved a pathological complete
response (pCR, n= 6) or that had a pathological partial response
with less than 10% of the initial tumor still present after treatment
and without axillary lymph node involvement (n = 7). NACT
non-responders included patients that still maintained more
than 50% of the initial tumor mass after treatment (n = 6),
or patients that developed brain, liver and/or lung metastasis
during NACT (n = 3) or patients that had an early relapse after
NACT (n= 8). Patients considered NACT responders were either
ER+ (30.77%), HER2 (38.46%), or TNBC (30.77%). Interestingly,
NACT responders showed higher levels of HLA-DR in CTLs
(p = 0.0003) and lower levels of HLA-DR in Tregs (p = 0.009)
when compared to the non-responders (Figure 2B). Again, the
percentage of T lymphocyte populations was not statistically
different between the two groups (Figure 2A). This finding is
independent of BC subtype (Figure S3). Indeed, the percentage
of CTLs, per se, was not sufficient to discriminate responders
from non-responders, across all three BC subtypes, while HLA-
DR expression levels in CTLs can segregate both groups,
especially in ER+ and TNBC (Figure S3). In HER2 breast
cancer, HLA-DR levels in CTLs was still higher in responders,
comparing with non-responders, although not statistically
significant. This may be explained by the fact that we only
have 3 samples from non-responders, including the only sample
where the HLA-DRhi in CTLs did not correspond to a NACT
responder.
In order to verify the predictive value of HLA-DR expression
in CTLs for NACT response, in general, we plotted the levels
of HLA-DR in CTLs and Tregs, of the total 30 biopsies in one
single column, regardless of the response (Figure 2C). Excitingly,
even with a small sample size, a robust separation of responders
(black triangles) and non-responders (gray dots) was observed
according to the expression level of HLA-DR, especially in CTLs
(Figure 2C).
Additionally, ROC curve analysis was performed, leading to
a statistically valid cut-off point for the HLA-DR expression
level in CTLs (8.943 - value above which patients are NACT
responders) and in Tregs (5.655 - value beneath which patients
are NACT responders). For HLA-DR-expressing CTLs, the area
under the ROC curve was 0.959, the sensitivity was 94.12% and
the specificity was 100%. For HLA-DR-expressing Tregs, the area
under the ROC curve was 0.849, the sensitivity was 81.25% and
the specificity was 75%. These results highlighted that, mainly,
HLA-DR-expressing CTLs evaluated in biopsies could predict
response to NACT with accuracy. To clarify the few borderline
cases, the analysis of HLA-DR+ Tregs can also be useful, since
there is a strong negative correlation between both markers
(Figure 1E).
It has been reported that chemotherapeutic agents are able to
alter the immune context of breast cancer, usually boosting anti-
tumor CTLs’ activity (20). Thus, post-NACT surgical samples,
non-matched with the pre-NACT samples, were analyzed by flow
cytometry. These specimens revealed that non-responders have
infiltrating CTLs with low levels of HLA-DR (p= 0.04) and Tregs
with high levels of HLA-DR (non-statistical) when compared to
responders (Figure S4), similar to specimens collected before the
treatment.
Other immune signatures of cancer immune status, namely
PD-1, PD-L1, CTLA4, T cell immunoglobulin and mucin
domain 3 (Tim3), IDO and IL-10, that potentially could be
used as biomarkers of NACT response were analyzed in the
pre-treatment biopsies. Although differences could be observed
between biopsies of NACT responders and non-responders,
none of them was statistically significant, as was HLA-DR in
CTLs. Moreover, we did not observe a segregation of these
groups of patients according to the level of expression in any
of these molecules in the tumor environment (Figure 2D). This
emphasizes that HLA-DRhi CTLs (with HLA-DR above the
threshold value) could potentially be implemented in the clinic
to distinguish NACT responders from non-responders.
HLA-DR-expressing CTLs Are Located
Preferably in Intraepithelial Tumor
Structures Than in the Surrounding Normal
Tissue
Besides the frequency and the type of immune cells in the tumor
tissue, their location could also be important to predict patients’
clinical outcome (21). For instance, it was found that disease-
free survival time is statistically shorter in colorectal carcinoma
patients without TILs in the center of the primary tumor mass
(22).
Therefore, we have assessed, by immunofluorescence,
selected formalin-fixed paraffin embedded (FFPE) tissue samples
matched with the previously analyzed by flow cytometry, and
evaluated where the HLA-DR+ CTLs are mainly located. We
observed that either in surgical samples from patients without
axillary lymph node metastasis and in biopsies of patients
with good response to NACT (Figure 3), HLA-DR-expressing
CTLs were mainly present in intraepithelial tumor structures.
Representative images in Figure 3 show a co-localization of
anti-CD8 and anti-HLA-DR within the tumor, while no co-
localization between these two markers was observed in the
tumor surrounding normal tissue. Indeed, outside the tumor
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FIGURE 2 | HLA-DR level in CTLs is a predictive factor of patients’ response to neoadjuvant chemotherapy (NACT). (A) Percentage of CTLs and Tregs in biopsies
from breast cancer patients that responded to NACT (R, black bar, n = 13, mean ± SD) and that had no response (NR, gray bar, n = 17, mean ± SD). The
percentage of each population was obtained in respect to the gate in single cells (Figure S1). (B) Level of HLA-DR in CTLs and Tregs in responders and
non-responders, expressed as the median fluorescent intensity of positive population normalized relatively to negative population (**p < 0.01, ***p < 0.001).
(C) HLA-DR expression in CTLs and Tregs with data for responders and non-responders plotted in a single column (black triangles and gray dots, respectively).
(D) The same analysis as in (C) was performed for other markers that theoretically could be used in the clinic: PD-L1, PD-1, CTLA4, IL-10, IDO and Tim3.
margins, CTLs were found, but no co-localization with HLA-DR
occurred, as HLA-DR staining was more spread throughout
the tissue. These results indicate that HLA-DR+ CTLs are
located in intraepithelial tumor structures rather than in the
surrounding normal tissue. This may suggest that the presence
of HLA-DR+ CTLs in a high proximity with tumor antigens
and tumor-released soluble factors, could lead to a more efficient
anti-tumor activity.
Circulating CTLs Maintain HLA-DR of
Tumor Infiltrating CTLs in BC Patients
To verify an association between the tumor immune
microenvironment and peripheral blood, blood samples
were also collected from 31 patients, prior to treatment
implementation, and immunophenotyped by flow cytometry.
Intriguingly, we observed that the expression of HLA-DR in
tumor infiltrating CTLs correlated with HLA-DR expression in
circulating CTLs (r = 0.58, p = 0.001) (Figure 4A). Moreover,
circulating CTLs have higher levels of HLA-DR in NACT
responders comparing with non-responders and healthy donors
(Figure 4B, p< 0.05), therefore allowing the distinction between
responders and non-responders (Figures 4B,C). Curiously,
non-responders have even lower levels of HLA-DR in circulating
CTLs than healthy donors (Figure 4B, p< 0.01).
IFN-γ and IL-10 levels in pre-treatment patients’ plasma,
assessed by ELISA, revealed that patients without axillary lymph
node invasion, as well as NACT responders, had higher levels
of IFN-γ (p = 0.004, p = 0.01, respectively, Figures 4D,F)
and lower levels of circulating IL-10 (p = 0.02, non-statistical,
respectively, Figures 4E,G), which is in agreement with the
presence of more activated or less activated circulating CTLs,
correspondingly.
Peripheral blood mononuclear cells (PBMCs) were isolated
from the blood of NACT responders and non-responders, at
the time of biopsy, and cultured under a canonical stimulus,
to clarify if they could recapitulate the characteristics of the
tumor infiltrating immune cells ex vivo, when exposed exactly
to the same conditions. PBMCs isolated from healthy donors
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FIGURE 3 | HLA-DR-expressing CTLs are localized in intraepithelial tumor structures of patients without axillary lymph node metastasis and in NACT responders.
Representative images of immunofluorescence experiments (n = 6) performed in slices of paraffin tissue of surgical BC samples of patients without axillary lymph
node metastasis (Node negative) and biopsies of NACT responders (Responders) for CTLs (green, Left panel) and HLA-DR (red, Middle panel). Nuclei are stained in
blue with DAPI and the three staining were merged (Right panel). Images from the tumor structures and from the tumor-surrounding tissue were acquired. Scale
bars: 20µm.
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FIGURE 4 | The profile of HLA-DR expression and cytokine production of intratumor CTLs is maintained in systemic CTLs. (A) Correlation between expression of
HLA-DR in systemic CTLs and tumor infiltrating CTLs (Spearman r = 0.58, p < 0.001). (B) HLA-DR expression in systemic CTLs in healthy donors (HD, gray bar,
n = 13, mean ± SD), NACT responders (R, white bar, n = 4, mean ± SD) and non-responders (NR, black bar, n = 5, mean ± SD), assessed by flow cytometry and
representing the median fluorescent intensity of positive population normalized relatively to the negative population. (C) Representative flow cytometry analysis of
HLA-DR in systemic T cells from blood collected at the time of biopsy of responders and non-responders. IFN-γ (D) and IL-10 (E) levels assessed by ELISA in plasma
of patients without axillary lymph node metastasis (gray bar, n = 9, mean ± SEM) and with axillary lymph node metastasis (black bar, n = 12, mean ± SEM). IFN-γ (F)
and IL-10 (G) levels assessed by ELISA in plasma from responders (R, white bar, n = 4, mean ± SEM) and non-responders (NR, black bar, n = 6, mean ± SEM). (H)
Expression of HLA-DR, assessed by flow cytometry, and representing the median fluorescent intensity of positive population normalized relatively to the negative
population, in CTLs and Tregs of ex vivo stimulated PBMCs isolated from healthy donors (HD, gray bar, n = 5, mean ± SEM), from responders (R, white bar, n = 4,
mean ± SEM) and from non-responders (NR, black bar, n = 5, mean ± SEM). *p < 0.05, **p < 0.01, ns, non-statistical.
were used as control. Interestingly, the expression of HLA-DR
in CTLs was higher in stimulated PBMCs of NACT responders
regarding stimulated PBMCs of non-responders (p = 0.02,
Figure 4H). This observation further supports that the tumor
immune features are maintained systemically and blood could
be used to specifically assess HLA-DR+ CTLs, which is a major
advantage for its potential use as a biomarker of response to
NACT.
HLA-DR-expressing CTLs Have Increased
Expression Levels of Effector Immune
Response-Related Molecules
To corroborate that HLA-DR+ CTLs are activated lymphocytes
with an anti-tumor activity profile, we assessed in pre-
treatment samples, infiltrated HLA-DR+ CTLs and HLA-DR
negative CTLs, the expression, by flow cytometry, of other
effector immune response-related molecules, such as IFN-γ and
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Granzyme B, which are the most important players of activated
CTLs. Interestingly, only HLA-DR+ CTLs expressed high levels
of IFN-γ and Granzyme B (Figure 5A), substantiating their
immune competent profile. Furthermore, we have analyzed the
expression level of these molecules also in HLA-DR+ CTLs
and HLA-DR negative CTLs from patients PBMCs (isolated
from pre-treatment blood). Similar to tumor, circulating HLA-
DR+ CTLs express more IFN-γ and Granzyme B than HLA-
DR negative CTLs (Figure 5A). Even if HLA-DR negative CTLs
from PBMCs had a higher level of Granzyme B expression when
compared to HLA-DR negative CTLs from tumor, the percentage
of HLA-DR+ CTLs from PBMCs that express Granzyme B, and
the corresponding median fluorescent intensity, is significantly
higher than in HLA-DR negative CTLs from PBMCs (p < 0.01,
data not shown).
Additionally, to further understand differences between HLA-
DR+ CTLs and HLA-DR negative CTLs, CTLs with and without
HLA-DR expression isolated from the blood were studied by
qRT-PCR. In this case, the expression of Granzyme B, Perforin,
TNFα and Eomes were assessed. HLA-DR+ CTLs expressed
higher levels of the cytolytic proteins Granzyme B (p= 0.02) and
Perforin (p = 0.03); Eomes (p = 0.03), involved in differentiation
of effector CTLs and the inflammatory cytokine TNFα (p= 0.03),
which also has anti-tumor properties, in comparison with HLA-
DR negative CTLs (Figure 5B).
Also, ex vivo stimulated PBMCs of responders (shown
to express more HLA-DR in CTLs than PBMCs of non-
responders—Figure 4H) have increased levels of IFN-γ
(p= 0.01) in CTLs and lower levels of IL-10 (p= 0.01), produced
by Th cells and/or Tregs respectively (Figures 5C,D), than
stimulated PBMCs of non-responders.
Altogether, these results suggest that CTLs with expression of
HLA-DR are active and effector lymphocytes that might have
a protective anti-tumor effect, which is in accordance to their
higher prevalence in BC without axillary lymph node metastasis
and/or in NACT responders.
HLA-DR Expression Level in CTLs
Negatively Correlates With the
Immunosuppressive and Pro-Tumor
Features of the Tumor Milieu
An anti-tumor or a pro-tumor immune response is elicited not
only by the immune cells within the tumor and their bioeffector
molecules, but also by tumor antigens and the expression of
cytokines, chemokines and other immune mediators released
by the cancer tissue. Thus, the stimulation of anti-tumor
CTLs’ activity should, at least in part, rely on the molecules
present in the tumor milieu. Interestingly, we have observed,
by flow cytometry analysis of pre-treatment BC samples,
that CTLs expressing HLA-DR were inversely correlated with
immunosuppressive activated Tregs (also expressing HLA-DR,
Figures 1E, 6). Moreover, they were also negatively correlated
with the expression of molecules from the non-immune
compartment that may co-opt the expression of typically innate
immune system-associated molecules to squelch the anti-tumor
immune program and/or enhance growth and survival of cancer
cells (Figure 6). Namely, HLA-DR expression level in CTLs
was negatively correlated with the expression level of TGF-β
(r = −0.45, p < 0.01), which increases the metastatic profile;
PD-L1 (r = −0.44, p < 0.0001), that inhibits infiltration and/or
activation of CTLs (23, 24); IL-6 (r = −0.51, p < 0.001), IL-8
(r = −0.56, p < 0.001) and IL-1β (r = −0.49, p < 0.001) that
are inflammatory cytokines that may act as growth factors to
sustain cancer cell proliferation and invasion (25–27). It was also
negatively correlated with IL-23/IL-12 (r = −0.56, p < 0.0001)
that is pro-inflammatory but can also impair CTLs’ activity
through the activation of Tregs (28) (Figure 6). On the other
hand, the expression level of HLA-DR in Tregs was positively
correlated with the expression of these pro-tumor molecules -
IL-1β (r = 0.47, p < 0.01), IL-23/IL-12 (r = 0.43, p < 0.01),
IL-6 (r = 0.48, p < 0.01) and IL-8 (r = 0.47, p < 0.001) – and,
additionally, IL-10 (r = 0.44, p < 0.0001) and IL-17 (r = 0.45,
p < 0.01), which could also undermine the activation of CTLs
and lead to tumor progression (29, 30) (Figure 6).
When the same analysis was performed with CTLs or Tregs
without accounting for HLA-DR expression, there was no
significant correlation between these cells and these molecules of
the tumor milieu (results not shown).
To better understand the contribution of cytokines or other
soluble factors present in the tumor milieu in the activation of
CTLs, we used a co-culture assay of HS 578T breast cancer cell
line with peripheral blood mononuclear cells (PBMCs) isolated
from patients. The assay was performed in several conditions:
PBMCs with HS 578T cell line, PBMCs with the supernatant
of the cell line alone, PBMCs plus a canonical stimulus, which
served as a positive control, or just PBMCs. Curiously, the
supernatant of the cell line alone increased the expression of
HLA-DR in CTLs (Figure S5).
Altogether, these data are in agreement with the supposition
that CTLs (and Tregs) bearing HLA-DR reflect the overall
immune status of the BC milieu.
DISCUSSION
Chemotherapy failure is the main reason for disease progression,
recurrence and cancer-related death. In the case of breast cancer
(BC), less than 50% of the patients have a pathological complete
response to neoadjuvant chemotherapy (NACT) (3, 4). Although
some efforts have been made in the past years, such as the
introduction of tumor infiltrating lymphocytes (TILs) as possible
biomarkers of response, especially in TNBC and HER2+ BC (7),
there is still no validated biomarker being routinely used in the
clinic.
The belief that NACT outcomemay depend on the presence of
TILs is related to the fact that chemotherapy leads to the release
of immunogenic signals, promoting immunogenic cell death,
which can potentially boost an anti-tumor immune response
(31). However, TILs are functionally heterogenic. For instance,
cytotoxic T lymphocytes (CTLs) have been strongly associated
with patient survival and response to therapy (7); regulatory
T cells (Tregs) have been associated with both good and bad
prognosis (6, 9); T helper 1 (Th1) cells have been related with
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FIGURE 5 | HLA-DR in CTLs reflects their activation and functional status. (A) Representation of a flow cytometry analysis of Granzyme B and IFN-γ expression in
HLA-DR+ CTLs and in HLA-DR negative CTLs from pre-treatment tumor samples and from PBMCs isolated from patients. (B) mRNA level of TNFα, Granzyme B
(GranzB), Perforin and Eomes in HLA-DR+ CTLs (black bars) and HLA-DR negative CTLs (white bars). mRNA level is expressed as the permillage (‰) of the
expression of the endogenous positive control (n = 4). (C) Percentage of CTLs expressing IFN-γ and (D) percentage of CD4+ T cells expressing IL-10, assessed by
flow cytometry, and representing the median fluorescent intensity of positive population normalized relatively to the negative population, in stimulated PBMCs isolated
from healthy donors (HD, gray bar, n = 5, mean ± SEM), from NACT responders (R, white bar, n = 4, mean ± SEM) and from non-responders (NR, black bar, n = 5,
mean ± SEM). *p < 0.05.
favorable clinical outcomes (32); whereas Th2 cells have been
reported to be associated with dampening of the anti-tumor
response (33). Therefore, it is controversial that simply the degree
of lymphocytic infiltration, assessed by immunohistochemistry in
sections of paraffin embedded tissue, has a predictive value of BC
patients’ response to NACT. Even infiltrating CTLs, per se, lack
the robustness that a predictive biomarker should have, because
their function can be hampered by tumor cells, through several
mechanisms. For instance, by expressing inhibitory molecules
like PD-L1 or by secreting immunosuppressive molecules such
as IL-10, TGF-β and IDO.
Thus, it is still crucial to establish a more accurate BC
“immunological status” that reflects the overall strength of
individual patients’ anti-tumor immune response that will
ultimately influence NACT efficiency.
In this study, we went beyond immunohistochemistry
evaluation of TILs in BC and analyzed, by flow cytometry,
T lymphocyte immune signatures, that could show their
activated/exhausted or anergic state and molecules present in the
tumor environment that are representative of the global tumor
immune status.
We found that CTLs expressing high levels of HLA-
DR, mainly located in intraepithelial tumor structures, are
characteristic of BC without axillary lymph node metastasis
and are strongly associated with good response to NACT
treatment, contrasting with CTLs with low or null expression
of this molecule. HLA-DR is an antigen presenting molecule
expressed at high levels on professional antigen presenting
cells, but its expression on effector T lymphocytes upon
their activation has also been intensively described in
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FIGURE 6 | HLA-DR expression level in CTLs and Tregs is differentially correlated with the immunosuppressive and pro-tumor features of the tumor environment. Heat
map of Spearman correlations between the expression level of HLA-DR in CTLs and the expression level of HLA-DR in Tregs; and between the expression level of
HLA-DR in both of these cells and the expression level of pro-tumor or immunosuppressive molecules from the tumor environment, namely PD-L1, TGF-b, IL-6, IL-1b,
IL-8, IL-23/IL-12, IL-10, and IL-17. The expression level of each molecule was assessed by flow cytometry and represents the median fluorescent intensity of positive
population normalized relatively to the negative population. The heat map is represented as a gradient from blue (negative correlations) to red (positive correlations).
Numbers in italic represent statistical significance of p < 0.01, numbers underlined represent p < 0.001 and numbers in italic and underlined represent p < 0.0001.
some diseases, such as auto-immune diseases and viral
infections (14, 15).
In the context of HIV patients, it has been described that
these HLA-DR+ CTLs exhibit a decreased proliferative potential
although retaining their cytolytic potential (34, 35). Additionally,
in severe aplastic anemia, an elevated number of HLA-DR+
CTLs detected in patients’ peripheral blood are responsible for
the excessive apoptosis of hematopoietic cells (36). However,
a suppressive effect of a subset of HLA-DR+ CTLs was also
reported (37). Here we confirmed that HLA-DR+ CTLs express
immune signatures of functionally activated, and not suppressive
CTLs, such as the production of IFN-γ, Granzyme B, Perforin,
TNFα, and Eomes. Thus, the infiltrating CTLs bearing HLA-DR
found in the analyzed samples should have an active participation
in the anti-tumor response, in conformity with the fact that
they were more elevated in patients without axillary lymph node
metastasis and with a better capacity to respond to NACT.
Tregs are recognized blockers of CTLs’ function and it is
known that HLA-DR also identifies functionally mature Tregs
(13). Thus, not surprisingly, HLA-DR expression level in Tregs
negatively correlates with its expression level in CTLs and is
associated with BCwith axillary lymph nodemetastasis andmore
abundant in biopsies of NACT non-responders.
In line with these former results, we also presented data
that negatively correlate the level of HLA-DR in CTLs with
the level of IL-6, IL-1β, IL-8, and IL-23/IL-12, which are
inflammatory cytokines that, at certain level in the tumor
microenvironment, could help the anti-tumor immune response
(38), but whose upregulation might also favor tumor progression
and metastasis (25–28). HLA-DR in CTLs was also inversely
correlated with the level of PD-L1 and TGF-β, which are,
respectively, a well-known inhibitory immune checkpoint and
an anti-inflammatory cytokine, which coordinately work to
dampen CTLs’ activity, directly or through the activation of
Tregs (23, 24). Likewise, HLA-DR expression in Tregs positively
correlated with all the aforementioned molecules from the tumor
milieu and, additionally, with IL-10 and IL-17, which also have
immunosuppressive functions (29, 30, 39).
In vitro experiments, with the supernatant of BC cell lines,
highlighted the fact that soluble factors released by tumor cells
are important to increase HLA-DR in CTLs, suggesting that these
tumor microenvironment molecules can modulate the immune
response and influence the activation state of CTLs, without the
requirement of contact with tumor cells.
In the other way around, we may say that the HLA-
DR expression in CTLs is a reflection of the general tumor
immune status. Indeed, an immunosuppressed environment will
be unable to stimulate an appropriate immune response and
should not give rise to HLA-DRhi CTLs. As cell-to-cell contact
and tumor-specific antigen presentation by antigen presenting
molecules are required to elicit a specific cytotoxic T cell response
against the tumor cells, we may infer that, in vivo, the antigens
presented by tumor cells, alongside with the soluble factors,
contribute to CTLs’ effector function.
The increase of HLA-DR at CTLs’ surface, upon stimulation,
could also be required to boost the anti-tumor immune response.
Indeed, HLA-DR+ CTLs were found to have the machinery
needed for antigen processing and loading on HLA-DR
Frontiers in Immunology | www.frontiersin.org 12 November 2018 | Volume 9 | Article 2605
Saraiva et al. HLA-DRhi CTLs Predict NACT Response
molecules and, additionally, could express CD86 and CD80,
which are the co-stimulatory molecules of antigen presenting
cells that are necessary for the proper T cell effector function (40).
Moreover, it was described that T cell-T cell synapsis occur to
allow T cells to secrete IFN-γ toward each other, compelling the
differentiation of more protective T cells (41). These T cell-T cell
interactions and mutual antigen presentation can be essential for
mounting a suitable anti-tumor response.
Notably, we observed that HLA-DR expression on tumor
infiltrating CTLs correlates to its expression in circulating
CTLs and, additionally, the analysis of HLA-DR level on CTLs
isolated from the patients’ blood could also be associated with
BC axillary lymph node invasion status and assist in the
prediction of patients’ response to NACT. Ex vivo assays indeed
corroborate that systemic CTLs maintain the profile encountered
in the tumor mass, as under similar stimulation, CTLs from
NACT responders increase even more their HLA-DR level and
produce more IFN-γ than CTLs from NACT non-responders.
These results imply that tumor immune status, reflected by
the HLA-DR level in CTLs, could also be easily assessed in
blood.
HLA-DR molecule, by itself, assessed in tumor cells, has been
reported to serve as a favorable prognostic marker for other types
of cancers, such as colorectal carcinoma (42) or glioma (43).
It was even shown that HLA-DR+ melanoma cells predict the
response to anti-PD-1/PD-L1 immunotherapy (44). However,
to our knowledge, the expression of HLA-DR in CTLs, besides
its extensive application in the study of viral infections and
chronic inflammatory diseases, was never recommended as a
biomarker in cancer. Our data suggest that HLA-DR+ CTLs,
assessed by flow cytometry, in BC patients prior to NACT, is
a sensitive and specific potential predictive factor for NACT
response. Moreover, this trait can be easily assessed in blood,
repeatedly if necessary. Further studies should be conducted in
an independent population, in order to validate the predictive
performance of HLA-DR+ CTLs in assisting the selection
of patients that will truly benefit from NACT, or promptly
directing them to alternative therapeutic strategies, such as the
combination of immunotherapies with standard chemotherapy.
Additionally, this marker also have the potential to be used
in clinical trial design to randomize good/bad responders to
evaluate novel treatments.
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